Regeneron Pharmaceuticals (REGN) director gets RSUs and 1,962 stock options

Rhea-AI Filing Summary

Regeneron Pharmaceuticals director George L. Sing reported new equity awards in company stock. On January 2, 2026, he acquired 155 shares of common stock at a price of $0.0 per share, described as time-based vesting restricted stock units that each represent a right to receive one share of common stock. On the same date, he received a non-qualified stock option to buy 1,962 shares of common stock at an exercise price of $772.76 per share, expiring on January 2, 2036.

Following these awards, Sing directly beneficially owns 31,007 shares of Regeneron common stock. Additional indirect holdings reported include 750 shares by his spouse, 400 shares by his spouse as custodian for their son, and 1,000 shares held in a trust for their son. A portion of the stock options becomes exercisable on the date of the first annual shareholder meeting following the grant, with the remainder exercisable on the first anniversary of the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SING GEORGE L

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A(1)		155	A	$0.0	31,007	D
Common Stock								750	I	by Spouse
Common Stock								400	I	by Spouse/Cust Son
Common Stock								1,000	I	by Trust for Son

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$772.76	01/02/2026		A		1,962		(2)	01/02/2036	Common Stock	1,962	$0.0	1,962	D

Explanation of Responses:

1. Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

2. On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

	/s/ George L. Sing	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did REGN director George L. Sing report on this Form 4?

George L. Sing, a director of Regeneron Pharmaceuticals, reported receiving 155 shares of common stock in the form of time-based vesting restricted stock units and a non-qualified stock option for 1,962 shares of common stock on January 2, 2026.

How many Regeneron (REGN) shares does George L. Sing own after the reported transactions?

After the reported transactions, George L. Sing beneficially owns 31,007 shares of Regeneron common stock directly. He also reports indirect holdings of 750 shares by his spouse, 400 shares by his spouse as custodian for their son, and 1,000 shares held in a trust for their son.

What are the terms of the stock options granted to George L. Sing at Regeneron?

The filing shows a grant of a non-qualified stock option giving George L. Sing the right to buy 1,962 shares of Regeneron common stock at an exercise price of $772.76 per share. These options expire on January 2, 2036.

When do George L. Sing’s Regeneron stock options become exercisable?

According to the footnote, on the date of Regeneron’s first annual meeting of shareholders following the grant date, a portion of the options, equal to the portion of one year that has passed since grant, will become exercisable. The remainder becomes exercisable on the first anniversary of the grant date.

What does the 155-share common stock award to George L. Sing represent?

The 155-share common stock entry reflects an acquisition of time-based vesting restricted stock units, with each unit representing a contingent right to receive one share of Regeneron’s common stock, at a reported price of $0.0 per share.

How are George L. Sing’s indirect Regeneron share holdings structured?

The filing lists indirect ownership of Regeneron common stock as 750 shares held by his spouse, 400 shares held by his spouse as custodian for their son, and 1,000 shares held by a trust for their son, all separate from his direct holdings.